Phase 1 vs Phase 2 — Infectious Disease Deal Valuation Comparison

Phase 1 Median Upfront

$194M

Total: $1.2B

Phase 2 Median Upfront

$604M

Total: $2.3B

Stage Premium

100%

Phase 2 premium over Phase 1

Phase 1 Royalties

5.8%-11.6%

vs Phase 2: 8.1%-16.3%

Model Your Deal

Market Analysis

The Phase 1 to Phase 2 transition in infectious disease represents a significant value inflection point. Phase 2 deals carry a median total deal value of $2.3B compared to $1.2B at Phase 1, a 100% premium reflecting clinical de-risking. Upfront payments increase from $194M to $604M.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Phase 1 to Phase 2 in infectious disease?

Phase 2 infectious disease deals command a 100% premium over Phase 1 in total deal value ($2.3B vs $1.2B). Upfronts increase from $194M to $604M, reflecting the de-risking value of clinical progression.

How do deal structures differ between Phase 1 and Phase 2 in infectious disease?

Phase 1 deals are more milestone-weighted (83% milestones), reflecting higher clinical risk. Phase 2 deals shift toward higher upfront allocations (26% upfront) as clinical de-risking reduces the need for contingent milestone structures.

When is the optimal time to license a infectious disease asset?

The optimal licensing window depends on strategic priorities. Phase 1 assets offer lower entry cost for licensees, while Phase 2 assets provide more certainty. The 100% premium from Phase 1 to Phase 2 reflects the value created by clinical data, making the transition point critical for deal timing.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Phase 1 vs Phase 2 — Infectious Disease Deal Valuation Comparison

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Phase 1 Infectious Disease Deals

Phase 2 Infectious Disease Deals

Phase 2 Deal Benchmarks

Ready to Calculate Your Deal Terms?